Mar 09, 2020 8:30am EDT Emerald Bioscience Announces Notice of Allowance from United States Patent Office for Proprietary Analog of Cannabidiol
Jan 30, 2020 8:30am EST Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum
Jan 13, 2020 8:30am EST Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones
Dec 10, 2019 8:30am EST Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform
Dec 09, 2019 8:30am EST Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues
